Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Net Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Margin for 15 consecutive years, with 4.63% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 428.0% to 4.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.31% through Dec 2025, down 712.0% year-over-year, with the annual reading at 4.31% for FY2025, 712.0% down from the prior year.
  • Net Margin for Q4 2025 was 4.63% at Gyre Therapeutics, down from 11.81% in the prior quarter.
  • The five-year high for Net Margin was 416.23% in Q4 2021, with the low at 1830.73% in Q1 2022.
  • Average Net Margin over 5 years is 339.4%, with a median of 3.03% recorded in 2024.
  • The sharpest move saw Net Margin tumbled -150475bps in 2021, then skyrocketed 183973bps in 2023.
  • Over 5 years, Net Margin stood at 416.23% in 2021, then tumbled by -107bps to 29.47% in 2022, then plummeted by -1163bps to 372.06% in 2023, then skyrocketed by 100bps to 0.36% in 2024, then tumbled by -1204bps to 4.63% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 4.63%, 11.81%, and 1.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.